Sprint Bioscience Q4 2023: A major step towards break-even
Research Update
2024-02-15
07:41
Sprint Bioscience recorded sales improved to SEK 10.9m from SEK 0.3m (Q4 2022), and operating cash flow improved by SEK -12.5m to a cash burn of SEK -2.7m. The main difference is the support from recurring services related to VADA and the VRK1 program. Sprint Bioscience can also negotiate with new potential partners for the DISA, NIMA and NASH programs. We adjust our base case to SEK 2.9 (SEK 3.2).
JU
Johan Unnerus
Disclosures and disclaimers